A New Preclinical Paradigm for Testing Anti-Aging Therapeutics.

@article{Ladiges2017ANP,
  title={A New Preclinical Paradigm for Testing Anti-Aging Therapeutics.},
  author={Warren C. Ladiges and Jessica M. Snyder and Erby Wilkinson and Denise M Imai and Tim P. Snider and Xuan Ge and M{\'a}rcia Aparecida Ciol and Christina Pettan-Brewer and Smitha Pankajavally Somanathan Pillai and John Frederick Morton and Ellen K. Quarles and Peter S. Rabinovitch and Laura J. Niedernhofer and Denny H. Liggitt},
  journal={The journals of gerontology. Series A, Biological sciences and medical sciences},
  year={2017},
  volume={72 6},
  pages={
          760-762
        }
}
Testing drugs for anti-aging effects has historically been conducted in mouse life-span studies, but are costly and time consuming, and more importantly, difficult to recapitulate in humans. In addition, life-span studies in mice are not well suited to testing drug combinations that target multiple factors involved in aging. Additional paradigms for testing therapeutics aimed at slowing aging are needed. A new paradigm, designated as the Geropathology Grading Platform (GGP), is based on a… CONTINUE READING